• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Devices Roar Into The Next Decade

Devices Roar Into The Next Decade

June 3, 2019 By Sponsored Content

medical devices

Medical device investments skyrocketed in 2018, and these trends are continuing into 2019. The activity now will influence healthcare for the next decade.

This year, the medical device and diagnostic industry saw record-breaking increases in the investment scene. As noted by Silicon Valley Bank’s (SVB) analysis, Trends in Healthcare Investments and Exits 2019, investing in medtech is a hot trend. The annual report highlighted record-breaking trends in investments and fundraising in the biopharma, medical devices, and diagnostics sectors.

Meanwhile, Evaluate Medtech’s World Preview 2018, Outlook to 2024 examines what players, technologies, and environments will drive the industry into the future. The report predicts that the global medtech industry will grow at 5.6% per year (CAGR) between 2017 and 2024, culminating in global sales of $595 billion by 2024.

The pipelines for biopharma, medical devices, and diagnostics proved alluring to investors in 2018. Investments in 2018 for all areas surpassed that of 2017 by nearly 50%, according to the SVB analysis. And the trend seems poised to continue. Here, we’ll look at the current environment for device investing, and consider the elements that will drive future success in the industry.

Traditional investments, a return to M&A, plus big exits

In the device arena, investments grew 40% from 2017 to 2018. Devices in cardiovascular, oncology, ophthalmology and non-invasive monitoring all saw an increase in Series A deals and dollars. Series A investments in cardiovascular more than doubled, moving from $44 million among 9 companies in 2017 to $172 million among 14 companies in 2018.

Although Series A funding was up, later-stage investments saw even greater climbs. For example, late-stage investments in cardio also more than doubled, going from $389 million for 28 companies to $871 million for 34 companies.

Traditional VCs dominated device investments. Many of the dollars came post-FDA approval so that investors could see quick (and lucrative) returns. The value of exits was up at $4.8B across 19 deals.

For the first time, venture-backed device M&A total upfront payments eclipsed all other sectors, reaching $3.5 billion. At $190M, 2018 had the largest median upfront device payment since 2013.

Boston Scientific led M&A, acquiring seven venture-backed companies in 2018. Boston Scientific also announced it will buy BTG plc (a large public company). Medtronic acquired a small public company, Mazor. Both new acquirers, like Teleflex and LivaNova, and stalwarts like J&J continue to be active. Moreover, new acquirers, like Penumbra, Massimo, Avanos, and Siemens Healthineers, could emerge as they look to build their R&D pipeline.

Companies and technologies

In the cardiovascular sector, deals focused on assist devices and mitral valve repair.

Both oncology and ophthalmology saw investments that involved surgical robotics. Tumor visualization and precision drug delivery also boosted oncology device investments.

Investments in ophthalmology and neurology highlighted a focus on surgical robotics and targeted drug delivery. The biggest deals included four that were valued over $150 million in 2017 and 2018 involving RxSight, Ivantis, Sight Sciences, and Avedro.

California and Massachusetts are the hotbeds of the healthcare investment scene, with the combination of Northern and Southern California forming a juggernaut of healthcare investing. The state drew 78 investment deals at $1.961 billion and launched 30 Series A deals totaling $311 million in funding.

Regulatory paths open up, R&D surges

One of the most important factors in the growth of device investments is the new regulatory pathways opening up, according to Evaluate Medtech’s report. The FDA has repeatedly stated its determination to speed medical devices to market. The number of innovative products granted first-time premarket approval grew to 51 in 2017, up from 40 the year before. De Novo 510(k) pathway deals had successful exits and total deal values far exceeding those of traditional 510(k) and PMA deals.

The ramp-up of all products submitted to the FDA shows a high pace of innovation. That pace will require continued R&D streams as the industry moves into the next decade.

The medtech market’s R&D spend is set to increase by 4.5% each year, reaching $39 billion by 2024. From the Evaluate Medtech report, large companies will lead the way.

Medtronic will spend $2.7 billion by 2024, growing at 2.8% CAGR between 2017 and 2024. Becton Dickinson and Edwards Lifesciences are forecast to increase their annual R&D spend the most, growing at a CAGR of 8.4% and 8.3%, respectively. Edwards Lifesciences and bioMérieux are expected to invest substantially more in R&D as a percentage of their medtech sales than the other top 20 companies, with an R&D investment rate of nearly 16% in 2024.

One of the keys to ensuring the focus stays on R&D and developing products that meet FDA standards is to improve cost containment in other expenditures. Clinical trial management constitutes a significant share of resources. Companies that aim to improve R&D and prove the science behind it will want to explore programs such as electronic data capture (EDC).

For example, Smith and Nephew, which will be among the top ten medical device companies in sales over the next five years recently consolidated all of its global studies on the Medidata Rave Clinical Cloud.

Medidata can create a seamless data flow from EDC to clinical trial management system on a single platform. This simplifies trial oversight, providing clinical operations teams with easy access and visualization of data to understand enrollment and progress of a clinical trial.

Using Medidata’s platform, Smith & Nephew can grow its study portfolio faster by breaking down data silos, allowing teams to focus on oversight activities that are critical to the success of a trial.

Conclusion

The healthcare industry has been slowly building up steam, laying the groundwork for better products and processes, that lead with digital advances and cloud computing. In the last two years, the industry has come roaring into its own with exciting technologies that aim to revolutionize healthcare.

Strong focus on R&D, advance of new technologies, a supportive FDA, and attention to data capture and management have led to unprecedented investment in the future of devices and the role they will play for healthcare in the future.

Sponsored content by Medidata Solutions

Filed Under: Sponsored Content Tagged With: medicaldevices, Medidata Solutions

In case you missed it

  • Once-a-week insulin dosing shows promise in studies
  • Abbott’s MitraClip doesn’t hinder oxygen levels, study shows
  • AdvaMed launches medtech podcast
  • Oncocyte acquires Chronix Biomedical
  • FDA nixes EUA for Lilly’s bamlanivimab
  • Seigla Medical gains CE mark for guide catheter extension
  • Contego Medical carotid stent wins CE mark approval
  • Pump problem prompts another Alaris recall
  • Virta Health raises $133M Series E for diabetes reversal tech
  • Canon Medical cardiac CT wins FDA clearance
  • MedTech 100 roundup: Industry skies to all-time high
  • DTW Podcast: How is Zimmer Biomet waging the ortho data war? Do medical devices carry physics-based biases?
  • Another BD Alaris infusion pump recall is Class I
  • 9 medical devices you should keep an eye out for in 2021
  • A quick history of the tech behind J&J, AstraZeneca’s COVID-19 vaccines
  • FDA finalizes rule to scale back how it regulates medtech software
  • Qorvo wins FDA nod for test that uses acoustic waves to detect COVID-19 antigens

RSS From Medical Design & Outsourcing

  • In situ cure technology molds next-gen medical implants
    Innovation in silicone technology has moved beyond defining specific material characteristics and into offering implantable devices that cure and form into shape inside the human body. Benny David, NuSil from Avantor Medical device manufacturers have long relied on highly purified silicone elastomers to fabricate components or entire devices for implantation. Now, recent innovations offer manufacturers… […]
  • How to prevent and troubleshoot short shots in medtech molding
    Deliberate processes to identify and remediate the problem can yield high-quality products and keep patients safe. Shane Vandekerkhof, RJG Short shots are among the most common and visually obvious quality issues most molders face, but they can cause fatal flaws in medical devices. Imagine if a luer lock connector was short. You run the risk… […]
  • AdvaMed launches medtech podcast
    AdvaMed today announced the launch of a new podcast, MedTech POV. AdvaMed president and CEO Scott Whitaker hosts the podcast, which covers the intersection of medtech and policy from a variety of perspectives. Each episode will feature discussions with medtech and healthcare policy leaders on issues that are driving the day — from business to… […]
  • This wearable could signal cytokine storms
    Researchers at the University of Texas at Dallas have developed a sweat sensor that could detect cytokine storms in patients suspected of having COVID-19 and other illnesses. Early on in the pandemic, doctors found that patients who developed a surge of pro-inflammatory immune proteins, called “cytokine storms,” were more often the sickest and at the… […]
  • How to evaluate laser performance for medical device manufacturing
    Laser processing provides automation and efficiencies that help meet FDA regulations and produce superior medical device components. David Locke, ACSYS Lasertechnik US Laser systems have become essential to the production of better-designed medical devices. The precision, repeatability and scale needed to manufacture next-generation medical products rely heavily on the advantages that lasers bring to contract… […]
  • EPA delayed notifying residents of ethylene oxide emissions
    The EPA delayed notifying neighbors of an Illinois medical device sterilization plant of ethylene oxide (EtO) emissions the agency measured in 2018, according to an inspector general’s report released yesterday. The report also says that “leadership” in the agency’s Office of Air and Radiation also failed to conduct public meetings with residents either near the… […]
  • 9 medical devices you should keep an eye out for in 2021
    The medical device industry weathered the COVID-19 pandemic well — and is now set to roll out a host of innovations in 2021. Economists generally expect the U.S. to see a boom as we emerge from the pandemic and resulting recession. Medtech companies appear set to ride the wave this year, with plans to seek… […]
  • Greenlight Guru to provide QMS to NIH diagnostics program
    NIH has chosen Greenlight Guru to provide quality management software for its COVID-19 rapid diagnostics program. The agency launched the Rapid Acceleration of Diagnostics (RADx) program in March 2020 to speed the development, commercialization and implementation COVID-19 testing technologies. As the only QMS provider currently available to all projects in the RADx program, Greenlight Guru… […]
  • MicroCare names CFO
    MicroCare (New Britain, Conn.) has announced the appointment of John Stardellis as the company’s new chief financial officer (CFO). Stardellis joins MicroCare with more than 20 years’ experience in a variety of finance, policy and operational leadership roles. Most recently, he served as CFO at i-Health, a division of DSM Nutritional Products. “John’s track record with… […]
  • Mayo Clinic helps launch two new companies for improved diagnostics
    Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched. Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release. Get the full story… […]
  • Intertek gains FDA nod for premarket device testing
    Intertek has won accreditation under an FDA pilot program for testing laboratories, the company said this week. The accreditation authorizes Intertek’s 12 “medical centers of excellence” to perform premarket testing of devices for the U.S. market. The Accreditation Scheme for Conformity Assessment pilot program is a voluntary program developed to provide increased confidence in testing… […]

Primary Sidebar

DeviceTalks by MassDevice · How Zimmer Biomet is competing in ortho’s data race; Do medical devices carry physics-based biases?

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS